Rekombinanter CBR1 Antikörper

Produktnummer ABIN7880172

Der Kaninchen Monoklonal anti-CBR1 Antikörper wird verwendet zum Nachweis von CBR1 in Proben von Human. Er wurde validiert für WB, IHC, ICC und IF.

Kurzübersicht für Rekombinanter CBR1 Antikörper (ABIN7880172)

Target: CBR1 (Carbonyl Reductase 1 (CBR1))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser CBR1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF)

Klon: 30C98

Produktdetails anti-CBR1 Antikörper

Verwendungszweck: CBR1 Antibody / Carbonyl reductase 1

Aufreinigung: Affinity-chromatography

Immunogen: A synthesized peptide derived from human CBR1 was used as the immunogen for the CBR1 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the CBR1 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store the CBR1 antibody at -20oC.

Details zu CBR1

Target: CBR1 (Carbonyl Reductase 1 (CBR1))

Andere Bezeichnung: CBR1

Hintergrund: CBR1 antibody detects Carbonyl reductase 1, encoded by the CBR1 gene. Carbonyl reductase 1 is an NADPH dependent enzyme that catalyzes the reduction of carbonyl containing compounds to their corresponding alcohols. This enzyme is part of the short chain dehydrogenase/reductase family and has a broad substrate spectrum, including xenobiotics, endogenous prostaglandins, and pharmacological agents. CBR1 antibody provides a valuable tool for studying drug metabolism, detoxification, and cellular defense mechanisms against reactive carbonyl species.

Carbonyl reductase 1 contributes to the metabolism of anthracycline drugs such as doxorubicin, converting them to less active alcohol metabolites. While this reduces anticancer activity, it also influences drug toxicity, particularly cardiotoxicity. Research with CBR1 antibody has been central to understanding interindividual variability in anthracycline metabolism and its impact on therapeutic outcomes. CBR1 also reduces prostaglandins and quinones, helping regulate inflammatory responses and oxidative stress signaling.

CBR1 has been linked to cancer, cardiovascular disease, and neurodegeneration. Overexpression has been reported in several tumors, where it may promote resistance to chemotherapy. Conversely, genetic polymorphisms in the CBR1 gene influence enzymatic activity and alter susceptibility to drug side effects. Using CBR1 antibody, researchers have demonstrated its tissue specific expression, with high levels in liver, kidney, and heart, reflecting its role in systemic detoxification. These findings underscore the enzyme's dual role in both protecting tissues and modulating pharmacological efficacy.

CBR1 antibody is applicable in western blotting, immunohistochemistry, and enzymatic activity assays. Western blotting demonstrates isoform expression across tissues, while immunohistochemistry reveals cytosolic distribution. Activity based assays combined with CBR1 antibody confirm enzyme function and response to inhibitors. These approaches allow detailed mapping of metabolic pathways influenced by Carbonyl reductase 1.

By providing validated CBR1 antibody reagents, NSJ Bioreagents supports research into drug metabolism, pharmacogenetics, and detoxification pathways. Detection of Carbonyl reductase 1 offers insights into how cellular defenses interact with therapeutic agents and environmental exposures.

UniProt: P16152